The bill potentially alters the landscape of health insurance in Illinois by ensuring that rebate amounts, which are often negotiated between insurance companies and pharmaceutical manufacturers, directly influence the upfront costs that consumers face at pharmacies. By applying excess rebate amounts to reduce premiums, the bill may provide a dual benefit of lowering both immediate costs for individuals and the overall cost of insurance plans. This could lead to greater accessibility to medications for people dependent on prescription therapies.
Summary
House Bill 4008 amends the Illinois Insurance Code by introducing provisions that directly impact the calculation of cost sharing for prescription drugs in accident and health insurance policies. As of January 1, 2026, the bill mandates that insurers must calculate a covered individual's cost sharing at the point of sale based on a price that reduces the cost by an amount equal to at least 100% of any rebates received linked to the dispensation or administration of the prescription drugs. This move is intended to enhance the affordability of prescriptions for individuals under these health insurance policies.
Contention
However, there are points of contention regarding the implementation of these measures. Critics may raise concerns about the feasibility of accurately calculating rebates at the point of sale and ensuring that insurers actually pass these savings onto consumers. Additionally, there may be worries about the administrative burden this may place on insurers, and whether it could inadvertently lead to higher overall costs for insurance providers, which could then be reflected in premium rates or coverage options.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.